Search Results
Search for other papers by Peter D Mark in
Google Scholar
PubMed
Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed
Department of Medicine O, Department of Clinical Physiology and Nuclear Medicine, Department of Clinical Physiology, Faculty of Health Sciences, Center for Functional and Diagnostic Imaging and Research, Centre of Endocrinology and Metabolism, Herlev University Hospital, Herlev Ringvej 75, Herlev DK‐2730, Denmark
Search for other papers by Claus L Petersen in
Google Scholar
PubMed
Department of Medicine O, Department of Clinical Physiology and Nuclear Medicine, Department of Clinical Physiology, Faculty of Health Sciences, Center for Functional and Diagnostic Imaging and Research, Centre of Endocrinology and Metabolism, Herlev University Hospital, Herlev Ringvej 75, Herlev DK‐2730, Denmark
Search for other papers by Andreas Kjaer in
Google Scholar
PubMed
Department of Medicine O, Department of Clinical Physiology and Nuclear Medicine, Department of Clinical Physiology, Faculty of Health Sciences, Center for Functional and Diagnostic Imaging and Research, Centre of Endocrinology and Metabolism, Herlev University Hospital, Herlev Ringvej 75, Herlev DK‐2730, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
Background Subclinical hyperthyroidism (SH) is defined by the biochemical pattern of reduced or undetectable serum thyroid-stimulating hormone (TSH) levels and thyroid hormone levels within the reference range. SH is seen with increasing frequency
Search for other papers by Thera P Links in
Google Scholar
PubMed
Search for other papers by Trynke van der Boom in
Google Scholar
PubMed
Search for other papers by Wouter T Zandee in
Google Scholar
PubMed
Search for other papers by Joop D Lefrandt in
Google Scholar
PubMed
the impact of overt and subclinical hyperthyroidism on the cardiovascular system. We will thereafter present the latest insights on the cardiac effects of thyroid suppression therapy for the treatment of thyroid cancer. Finally, we will show new
Search for other papers by L E Zijlstra in
Google Scholar
PubMed
Search for other papers by D M van Velzen in
Google Scholar
PubMed
Search for other papers by S Simsek in
Google Scholar
PubMed
Search for other papers by S P Mooijaart in
Google Scholar
PubMed
Department of Internal Medicine, HagaHospital, The Hague, The Netherlands
Search for other papers by M van Buren in
Google Scholar
PubMed
Search for other papers by D J Stott in
Google Scholar
PubMed
Search for other papers by I Ford in
Google Scholar
PubMed
Search for other papers by J W Jukema in
Google Scholar
PubMed
Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by S Trompet in
Google Scholar
PubMed
Introduction Subclinical hyperthyroidism has been linked to atrial fibrillation and coronary artery calcification, whereas subclinical hypothyroidism has been associated with hypercholesterolemia and atherosclerosis ( 1 , 2 ). Despite these
Search for other papers by Xingyao Tang in
Google Scholar
PubMed
Search for other papers by Zhi-Hui Song in
Google Scholar
PubMed
Search for other papers by Dawei Wang in
Google Scholar
PubMed
Search for other papers by Jinkui Yang in
Google Scholar
PubMed
Search for other papers by Marly Augusto Cardoso in
Google Scholar
PubMed
Search for other papers by Jian-Bo Zhou in
Google Scholar
PubMed
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
Search for other papers by Rafael Simó in
Google Scholar
PubMed
factor for dementia, promotes neurocognitive function and regulation metabolic processes ( 4 ). Thyroid dysfunction, including clinical hyperthyroidism, subclinical hyperthyroidism, subclinical hypothyroidism, and clinical hypothyroidism, has been
Search for other papers by Xin He in
Google Scholar
PubMed
Search for other papers by Qin Yan in
Google Scholar
PubMed
Search for other papers by Chazhen Liu in
Google Scholar
PubMed
Search for other papers by Zhengyuan Wang in
Google Scholar
PubMed
Search for other papers by Ping Liao in
Google Scholar
PubMed
Search for other papers by Tong Liu in
Google Scholar
PubMed
Search for other papers by Zehuan Shi in
Google Scholar
PubMed
Search for other papers by Qi Song in
Google Scholar
PubMed
Search for other papers by Xueying Cui in
Google Scholar
PubMed
Search for other papers by Wenjing Wang in
Google Scholar
PubMed
Search for other papers by Jiajie Zang in
Google Scholar
PubMed
hyperthyroidism was defined as TSH concentration below the 2.5th percentile with an FT4 concentration above the 97.5thpercentile, while subclinical hyperthyroidism was defined as TSH concentration below the 2.5th percentile with an FT4 concentration within the
Search for other papers by Till Ittermann in
Google Scholar
PubMed
Department of Zoology, Islamia College Peshawar (CU), Peshawar, Pakistan
Search for other papers by Rehman Mehmood Khattak in
Google Scholar
PubMed
Search for other papers by Marcello R P Markus in
Google Scholar
PubMed
Search for other papers by Jens-Peter Kühn in
Google Scholar
PubMed
Search for other papers by Marie-Luise Kromrey in
Google Scholar
PubMed
Search for other papers by Giovanni Targher in
Google Scholar
PubMed
Search for other papers by Antje Steveling in
Google Scholar
PubMed
DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine, Greifswald, Germany
Search for other papers by Matthias Nauck in
Google Scholar
PubMed
Search for other papers by Henry Völzke in
Google Scholar
PubMed
to the biologically active form fT3. In obese individuals, we observed an inverse association between serum TSH levels and NAFLD, which may indicate that a subclinical hyperthyroid state is associated with NAFLD particularly in obese individuals
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel
Search for other papers by Elena Izkhakov in
Google Scholar
PubMed
Community Division, Clalit Health Services, Tel Aviv, Israel
The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel
Search for other papers by Joseph Meyerovitch in
Google Scholar
PubMed
Search for other papers by Micha Barchana in
Google Scholar
PubMed
Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Search for other papers by Yacov Shacham in
Google Scholar
PubMed
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Search for other papers by Naftali Stern in
Google Scholar
PubMed
National Cancer Registry, Israel Center for Disease Control, Ministry of Health, Israel, Ramat Gan, Israel
Search for other papers by Lital Keinan-Boker in
Google Scholar
PubMed
benign disease ( 23 ). TSH suppression therapy caused a state of subclinical hyperthyroidism and is a part of TC treatment. The current study does not have any data on the exact dosages of levothyroxine or the TSH-suppressive levels that were achieved
Search for other papers by Ulla Schmidt in
Google Scholar
PubMed
Search for other papers by Birte Nygaard in
Google Scholar
PubMed
Search for other papers by Ebbe Winther Jensen in
Google Scholar
PubMed
Search for other papers by Jan Kvetny in
Google Scholar
PubMed
Search for other papers by Anne Jarløv in
Google Scholar
PubMed
Endocrine Unit, Department of Medicine, Endocrine Unit, Faculty of Health Sciences, Department of Medicine O, Herlev University Hospital, Herlev Ringvej, DK-2730 Herlev, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
-known enhanced bone turnover in subclinical hyperthyroidism, both exogenous (due to T 4 treatment) and endogenous (21) . However, no difference was found in the PINP levels of patients on T 4 vs T 3 monotherapy (12) . It is not clear whether our findings are
Search for other papers by Marek Niedziela in
Google Scholar
PubMed
-Albright syndrome (MAS), a sporadic genetic disease, is caused by an activating mutation of GNAS1 for the Gs alpha membrane-associated protein, mediating the TSH-induced and other hormone-induced activation of adenylyl cyclase; subclinical hyperthyroidism can be
Search for other papers by Akinori Sairaku in
Google Scholar
PubMed
Search for other papers by Yukiko Nakano in
Google Scholar
PubMed
Search for other papers by Yuko Uchimura in
Google Scholar
PubMed
Search for other papers by Takehito Tokuyama in
Google Scholar
PubMed
Search for other papers by Hiroshi Kawazoe in
Google Scholar
PubMed
Search for other papers by Yoshikazu Watanabe in
Google Scholar
PubMed
Search for other papers by Hiroya Matsumura in
Google Scholar
PubMed
Search for other papers by Yasuki Kihara in
Google Scholar
PubMed
, cardiomyopathy or moderate or severe valvular disorders, severe renal dysfunction, overt or subclinical hyperthyroidism, or overt hypothyroidism. The patients who were taking any thyroid medications were also excluded. The types of AF were defined according to